EDTA chelation therapy for atherosclerosis and degenerative diseases: Implausibility and paradoxical oxidant effects

Scientific Review of Alternative Medicine

Volumn 6, Issue 1, 2002, Pages 17-22

  Green, Saul ^a,b   Sampson, Wallace ^c  

^a Zol Consultants Inc   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM; COPPER; EDETIC ACID; FREE RADICAL; HEAVY METAL; HEPARIN; IRON; LIDOCAINE; MAGNESIUM; MAGNESIUM CHLORIDE; METAL; METAL ION; PYRIDOXAMINE; REDUCING AGENT; VITAMIN B COMPLEX;

AEROBIC METABOLISM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW DEPRESSION; CALCIUM METABOLISM; CHELATION THERAPY; CHEMISTRY; CLINICAL PROTOCOL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EXCRETION; DRUG HYPERSENSITIVITY; HEALTH CARE COST; HEART ARRHYTHMIA; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HYPOCALCEMIA; HYPOTENSION; IN VITRO STUDY; KIDNEY TUBULE NECROSIS; MEDICAL ETHICS; MEDICOLEGAL ASPECT; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; REVIEW; SIDE EFFECT; SUPPLEMENTATION; TETANY;

EID: 0036893602     PISSN: 10950656     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Cranton E, Brecher A, Frackleton J. Bypassing Bypass: A Non-Surgical Therapy for Improving Circulation and Slowing the Aging Process. Hampton Roads, Va: Medex Inc., 1980.
2. Trowbridge J, Gordon G. Chelation Therapy. Greenwich, CT: Devin Adair, 1985.
3. Walker M, Gordon G. The Chelation Answer. Evans and Co, New York, 1982
4. Cranton E. A Textbook on EDTA Chelation Therapy. New York, NY: Human Sciences Press, Inc.; 1990.
5. Clarke N. EDTA chelation therapy. Am J Cardiol. 1960;6:233-236.
6. Damjanov I, Linder J. Anderson's Pathology. St. Louis: Mosby Yearbook; 1996.
7. Goodman A, Rall T, Nies A, Taylor P, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. New York, NY: Pergamon Press; 1990.
8. Haynes RC. Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Goodman A, Rall T, Nies A, Taylor P, eds. Goodman and Gilman's Pharmacologic Basis of Therapeutics. New York, NY: Pergamon Press; 1990:1500-1501.
9. Guldager B, Brixen KT, Jorgensen SJ, Nielsen SK, Mosekilde L, Jeines R. Effects of intravenous EDTA on serum parathormone (1-84) and biochemical markers of bone turnover. Dan Med Bull. 1993;40(5):627-630.
10. 2 EDTA. Am J Med Sci. 1956;230:654-666.
11. Meltzer LE, Ural E, Kitchell Jr. In: Seven M, ed. Metal Binding in Medicine. Philadelphia, Pa: Lippincott; 1960.
12. Kitchell JR. The treatment of coronary artery disease with disodium EDTA: a reappraisal. Am J Cardiol. 1963;11:501-506.
13. Chappell L. Chelation therapy should be used more commonly in treatment of vascular disease. Alt Ther Health Med. 1995;1(2):53-57.
14. Chappel L, Stahl J. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139-160.
15. Chappell L, Stahl J, Evans R. EDTA chelation therapy for vascular disease: a meta-analysis using unpublished data. J Adv Med. 1994;7:131-142.
16. Margolis S. Chelation therapy is ineffective for treatment of peripheral vascular disease. Alt Ther Health Med. 1995;1(2): 53-57.
17. Klaessen C. Heavy metals and heavy metal antagonists in the pharmacological basis of therapy. In: Goodman A, Rall T, Nies A, Taylor P, eds. Goodman and Gilman's Pharmacologic Basis of Therapeutics. New York, NY: Pergamon Press, 1990.
18. Allain P. Effects of an EDTA infusion on the urinary elimination of several mineral elements in healthy subjects. Br J Clin Pharm. 1991;31:347-349.
19. Guldager B, Jorgensen P, Grandjean P. Metal excretion in patients with intermittent claudication treated with intravenous disodium EDTA. Clin Chem. 1996;42(12): 1938-1942.
20. Green S, Mazur A, Shorr E. Mechanisms of catalytic oxidation of adrenalin by ferritin iron. J Biol Chem. 1956;220:237-255.
21. Herbert V, Shaw S, Jayatilleke E. Vitamin C-driven free radical generation from iron. J Nutr. 1996;126(Suppl 14):1213S-1220S.
22. Rosenblatt D, Aaronson A. CaEDTA toxicity: Time and dose response studies on intestinal DNA synthesis. Exp Mol Path. 1978;28:202-205.
23. Swenerton H, Hurley L. Teratogenic effects of chelating agents. Science. 1971;173:62-65.
24. Kimmel C. Studies on the mechanism of EDTA teratogenesis. Teratology. 1975;12:330-335.
25. Planas-Bohne Y, Lohbrier X. CaEDTA evokes biochemical and morphological (teratogenic) effect in the intestine, liver, kidneys, and blood forming organs in rats: Toxicological studies. In: Diagnosis and Treatment of Incorporated Radionucleotides. Vienna, Austria: Intern Atom Energy Agency, 1976.
26. Brownie C. Teratogenic effect of CaEDTA in rats. Toxicol Appl Pharm. 1986;82:426-429.
27. Saltman P. Oxidative stress: A radical view. Semin Hematol. 1989;26(4):249-256.
28. Dreyer GB, Dervan PB. Sequence-specific cleavage of single-stranded DNA: Oligodeoxynucleotide-EDTA Fe(II). Proc Nat Acad Sci USA 1985;82:968-972.
29. O'Brien S, Kelly S, Dolphin P, Russell J. Chelation in the JCR:LA-cp rat: Experimental assessment of a putative anti-atherosclerotic treatment. Clin Invest Med. 2000;23(2):124-131.
30. Anon. Council on Scientific Affairs: Chelation therapy. JAMA. 1983;250(5):672.
31. Diehm C. Wonder remedy chelation - Claims and reality. Zeit Deutch Herzstiftung. 1986;10:11-15.
32. Hopf R. The test of alternative medicine: Chelation therapy. Zeit f Kardiology. 1987;76:2.
33. Hopf R. Test of an alternative medicine. Zeit Deutsch Herzstiftung. 1987;15:6-16.
34. Guldager B, Jelnes R, Jorgensen S, et al. EDTA treatment of intermittent claudication - A double-blinded, placebo-controlled study. J Int Med. 1992;231:261-267.
35. Van Rij A, Solomon C, Packer S, Hopkins W. Chelation therapy for intermittent claudication. Circul. 1994;90(3):1194-1199.
36. Knudtson, ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: A randomized, controlled trial. JAMA. 2002;287:481-486.
37. Ernst E. Chelation therapy for peripheral arterial disease: A systematic review. Circulation. 1997;96(3):1931-1933.
38. Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am Heart J. 2000;140(1):139-141.
39. Sampson W. Pharmacology of chelation therapy. Sci Rev Alt Med. 1997;1(1):25-27.